Voxel dispute slated for arbitration
A dispute with its manufacturing partner has prompted holographicdisplay developer Voxel of Laguna Hills, CA, to begin lookingfor an alternative source for development and manufacturing ofits Voxcam systems. The dispute began in December, when
A dispute with its manufacturing partner has prompted holographicdisplay developer Voxel of Laguna Hills, CA, to begin lookingfor an alternative source for development and manufacturing ofits Voxcam systems. The dispute began in December, when Voxelannounced that it believed its current vendorlaser systemdeveloper General Scanningwas in breach of contract for allegedlyfailing to meet engineering specifications and delivery datesfor the Voxcam imager, a central element in Voxel's digital holographysystem (SCAN 1/22/97).
The dispute between Voxel and General Scanning, of Watertown,MA, is now headed for binding arbitration. Meanwhile, Voxel hasdecided to accelerate its alternative manufacturing program dueto several factors, such as tests by the company that Voxel believesconfirm the engineering shortcomings at the root of its disputewith General Scanning. Under its contract with General Scanning,Voxel had been prohibited from using another manufacturing partner,but that provision was waived when the dispute went to arbitration.
Voxel's alternative manufacturing program will include securingsubsystems from qualified vendors and will also include performingfinal assembly and testing in-house for a pilot production run.A system integrator for volume manufacturing will also be selected.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
